Taiwanese Hemophiliacs Infected by US Made HIV-Contaminated Medications: Exhibits

• Szmuness 1975 “On the Role of Sexual Behavior in the Spread of Hepatitis B Infection”
• Exhibit 1: Cutter Memo to Taiwan supplier re sales of AHF since 1977, 2 April 1985
• Exhibit 2: Cutter Memo re meeting with Taiwan Dept of Health, 4-5 Feb 1997
• Exhibit 3: Cutter Memo re heat treatment killing AIDS virus, 17 May 1984
• Exhibit 4: Cutter Note re AHF study and chimpanzees developing AIDS-like symptoms, 14 Dec 1982
• Exhibit 5: July 1982 MMWR reporting hemophiliacs showing symptoms of
  disease observed in gay men
• Exhibit 6: Oct 1984 MMWR reporting increasing cases of AIDS in hemophiliacs
• Exhibit 7: Cutter Memo re plasma screening test recommended by the FDA, 19 Dec 1983
• Exhibit 8: Cutter Memo re FDA asking Cutter to voluntarily exclude gays from plasma collection, 30 Aug 1982
• Exhibit 9: Cutter Memo re FDA asking Cutter to exclude high risk donors, including prisoners, 21 Dec 1982
• Exhibit 10: Advertisements in various gay magazines for plasma donors exposed to hepatitis
• Exhibit 11: Cutter letter to Warden of Arizona State Prison in Florence re FDA concern re prisoner plasma, 19 Jan 1983
• Exhibit 12: Letter from Cutter’s Oakland Plasma Center to Cutter, that center was found to be in non-compliance re plasma collection from IV drug users, 19 May 1981
• Exhibit 13: Cutter Memo re FDA asking for exclusion of plasma from high risk donors, 13 Dec 1982
• Exhibit 14: Transcript of Steven Ojala (Cutter) presentation to FDA Committee opposing mandatory recalls, 19 July 1983
• Exhibit 15: Internal Cutter Memo from Mozen that heat treated AHF would probably be safer, 4 Jan 1983
• Exhibit 16: Letter from FDA to Hyland / Travenol approving their heat treatment license, 21 March 1983
• Exhibit 17: Letter from FDA to Miles (Cutter) approving their heat treatment license, 29 Feb 1984
• Exhibit 18: Letter from Cutter to FDA, date 9 Aug 1985, that they ceased making and distributing non-heat treated product on 21 June 1985
• Exhibit 19: Letter from FDA to Miles/Cutter acknowledging Cutter’s letter of 9 Aug 1985
• Exhibit 20: Confidential Cutter Memo of 15 Nov 1984 regarding excess inventory of non-heated AHF
• Exhibit 21: Cutter Telex of 29 Nov 1984 regarding continued sale of non-heated AHF to the Far East
• Exhibit 22: Cutter’s 1984 Far East Marketing Memo stating that a recall would cost
  Cutter $2 Million during 1984
• Exhibit 23: Cutter’s 1985 Far East Marketing Memo stating Cutter has no immediate plans to stop selling non-heated AHF, because AIDS was not yet an issue in the Far East, and that “hysteria over AIDS” could cost them to lose sales and profit
• Exhibit 24: Telex from Cutter to Hong Kong supplier, dated 6 May 1985, stating that non-heated product is still being sold in Taiwan and other countries, describing non-heated AHF as “the same fine product”
• Exhibit 25: Cutter Memo dated 30 May 1985, regarding FDA request to Cutter to stop making
  non-heated AHF
• Exhibit 26: Cutter telex dated 31 Oct 1983, recalling AHF lots containing plasma from Austin donor who died of AIDS
• Exhibit 27: Cutter Memo of 4 Nov 1983 regarding recall due to Austin donor “diagnosed
  as having AIDS”
• Exhibit 28: Cutter Telex to Taiwan supplier regarding recall, saying donor was “suspected of AIDS”
• Exhibit 29: Cutter Letter introducing sales manual for heat treated AHF, dated 12 April 1984
• Exhibit 31: Cutter Marketing Bulletin dated 26 June 1985 saying “Effective immediately, no further exports of non-heat treated AHF” would be made
• Exhibit 32: Cutter telex to Taiwan supplier, dated 20 Sept 1985, offering exchange of heat-treated AHF for the non-heat treated AHF